• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.08%

    More On SPARC.NS



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Sun Pharma Advanced Research Company Limited (SPARC.NS)

    403.45 Up 6.60(1.66%) 6:00AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Sun Pharma Advanced Research Company Limited
    Sun Pharma Advanced Research Centre
    Akota Road
    Vadodara, 390020
    India - Map
    Website: http://www.sunpharma.in

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:N/A

    Business Summary 

    Sun Pharma Advanced Research Company Limited, a pharmaceutical company, is engaged in research and development of drugs and delivery systems. The company develops products in oncology, ophthalmology, CNS, respiratory areas. It develops Sun K706, a novel tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia; Sun 0597, a topical glucocorticoid for the treatment of allergic rhinitis, asthma, and other applications; and SUN-L731, an oral LTD4 antagonist for asthma and allergic rhinitis. The company also offers Baclofen GRS for the treatment of spasticity; Wrap Matrix controlled release systems, including Levetiracetam ER for epilepsy and Venlafaxine ER for depression; Paclitaxel injection concentrate for nanodispersion for the treatment of breast cancer; and Docetaxel injection concentrate for nanodispersion. In addition, it provides Somatostain analogues are used to treat acromegaly and growth hormone dependent cancers; BKC- free Latanoprost and Latanoprost + Timolol used for the treatment for glaucoma; and Fluticasone + Salmeterol DPI for the treatment of asthma. The company operates in India and internationally. Sun Pharma Advanced Research Company Limited is based in Vadodara, India.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Sun Pharma Advanced Research Company Limited

    Key Executives 
    Mr. Dilip Shantilal Shanghvi , 59
    Chairman and Managing Director
    Mr. Anil Raghavan ,
    Chief Exec. Officer
    Mr. Debashis Day ,
    Company Sec.
    Dr. Subhas Bhowmick , 59
    VP of R&D (Formulation)
    Dr. K. Shivramchandra , 60
    VP of R&D (Analytical Devel.)
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in INR.